'Modest support' for PFS as OS surrogate in HER2-positive metastatic breast cancer
Progression-free survival only moderately correlates with overall survival at the individual and trial level in patients with HER2-positive metastatic breast cancer treated with HER2-targeted agents, say researchers.
More... |
All times are GMT -7. The time now is 04:37 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021